InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.715

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$341 Change in Director's Interest Notice - J Fairley 1 Oct 2021 2:31PM $1.300 $0.715 fallen by 45%
$341 Notification of cessation of securities - SPL 1 Oct 2021 2:24PM $1.305 $0.715 fallen by 45.21%
$341 2021 Annual General Meeting 1 Oct 2021 2:18PM $1.300 $0.715 fallen by 45%
$341 US patent issued for DEP cabazitaxel nanoparticle 15 Sep 2021 9:17AM $1.310 $0.715 fallen by 45.42%
$341 Application for quotation of securities - SPL 13 Sep 2021 4:41PM $1.300 $0.715 fallen by 45%
$341 Change in Director's Interest Notice - Z Peach 31 Aug 2021 4:14PM $1.205 $0.715 fallen by 40.66%
$341 Change in Director's Interest Notice - J Fairley 30 Aug 2021 10:44AM $1.145 $0.715 fallen by 37.55%
$341 Change in Director's Interest Notice - R Thomas 27 Aug 2021 2:52PM $1.135 $0.715 fallen by 37%
$341 Change in Director's Interest Notice - L Cheng 27 Aug 2021 2:48PM $1.145 $0.715 fallen by 37.55%
$341 Appendix 4G - Corporate Governance Statement 26 Aug 2021 9:39AM $1.270 $0.715 fallen by 43.70%
$341 Starpharma annual report and full year financial results 26 Aug 2021 9:28AM $1.270 $0.715 fallen by 43.70%
$341 VIRALEZE Protects Against SARS-CoV-2 in Challenge Model 23 Aug 2021 10:23AM $1.195 $0.715 fallen by 40.17%
$341 VIRALEZE well tolerated in multiple dose clinical study 17 Aug 2021 10:29AM $1.315 $0.715 fallen by 45.63%
$341 Initial Director's Interest Notice 2 Aug 2021 11:40AM $1.355 $0.715 fallen by 47.23%
$341 Quarterly Cashflow and Activities Report 30 Jul 2021 10:28AM $1.348 $0.715 fallen by 46.94%
$341 Resignation of non-executive director 29 Jul 2021 4:22PM $1.350 $0.715 fallen by 47.04%
$341 Lynda Cheng appointed as non-executive director 28 Jul 2021 10:37AM $1.300 $0.715 fallen by 45%
$341 Starpharma to present DEP platform at CRS Annual Meeting 27 Jul 2021 5:45PM $1.360 $0.715 fallen by 47.43%
$341 VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant 27 Jul 2021 9:49AM $1.260 $0.715 fallen by 43.25%
$341 TGA infringement notices for alleged advertising 5 Jul 2021 9:33AM $1.495 $0.715 fallen by 52.17%
$341 Change in substantial holding 2 Jul 2021 8:25AM $1.530 $0.715 fallen by 53.27%
$341 Starpharma to present at Virtual Life Science Investor Forum 24 Jun 2021 12:08PM $1.580 $0.715 fallen by 54.75%
$341 VIRALEZE UK Update 21 Jun 2021 9:37AM $1.700 $0.715 fallen by 57.94%
$341 VIRALEZE SPL7013 virucidal against multiple COVID variants 18 Jun 2021 9:23AM $1.555 $0.715 fallen by 54.02%
$341 VIRALEZE antiviral nasal spray registered for sale in India 11 Jun 2021 2:27PM $1.610 $0.715 fallen by 55.59%

301 - 325 of 882 results

Page 13 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.